Hudson Bay Capital Management
ASBPW

Hudson Bay Capital Management’s Aspire Biopharma Warrant ASBPW Stock Holding History

Hudson Bay Capital Management’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-97,474
Closed -$12K – 1398
2022
Q2 		$12K Buy
+97,474
New +$21.2K ﹤0.01% 1223

Other funds holding ASBPW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Hudson Bay Capital Management's ASBPW Position: Q3 2022 in Review

Hudson Bay Capital Management sold out of Aspire Biopharma Warrant (ASBPW) in Q3 2022, closing a stake of 97,474 shares — an estimated $12K sold.

Hudson Bay Capital Management first reported a position in ASBPW in Q2 2022 and held it in 1 quarter. The position peaked at $12K in Q2 2022. 36 funds tracked by Wall St. Rank hold ASBPW as of Q3 2022.

  • Hudson Bay Capital Management reported no remaining Aspire Biopharma Warrant position as of Q3 2022 after selling out during the quarter.
  • Hudson Bay Capital Management sold 97,474 Aspire Biopharma Warrant shares in Q3 2022, an estimated $12K.
  • Hudson Bay Capital Management first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 1 quarter.
  • Hudson Bay Capital Management's Aspire Biopharma Warrant position peaked at $12K in Q2 2022.
  • 36 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q3 2022.

Based on Hudson Bay Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.